Back to search results

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Abroad (travel likely)RecruitingPHASE2

Conditions

Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Yale University, New Haven, Connecticut, United States

    Contact: Study coordinator (Myeloma Clinical Research Team) · daniel.moncayo@yale.edu · 203-500-0834
    Contact: Principal Investigator (Noffar Bar)

  • Wilmot Cancer Center, Clinical Trial Office of the University of Rochester Medical Center, Rochester, New York, United States

    Contact: Study coordinator (Marina Crouch) · WCICTOResearch@URMC.Rochester.edu · 585-275-5863
    Contact: Principal Investigator (Brea Lipe, MD)
Study leads

  • Noffar Bar, MD

    Principal Investigator

    Yale University

View source on ClinicalTrials.gov(opens in a new tab)